In the News | Friends of Cancer Research

You are here

In the News

eCancer News - ASCO 2019: Use of broader criteria for clinical trial enrolment would double number of eligible patients with lung cancer

A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria, as proposed by ASCO and Friends of Cancer Research in 2017, would nearly double the percentage of patients eligible to enrol in clinical trials – from 52.3% to 98.5%.


The expanded clinical trial eligibility criteria would allow aNSCLC patients with brain metastases, previous or concurrent cancers, and limited kidney function to enrol in clinical trials.


eCancer TV - Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials

Dr R. Donald Harvey presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from a study looking at using ASCO’s CancerLinQ database to look expanding clinical trial inclusion criteria.


Researchers looked at 10,500 health records of advanced non-small cell lung cancer and compared the traditional criteria with the proposed new criteria from ASCO and Friends of Cancer Research.


Science Daily - Immunotherapy drug found safe in treating cancer patients with HIV, study suggests

The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA®.


PharmaForum - Relax criteria to increase sign-ups to cancer trials, says ASCO

Only 3% of patients with cancer in the US enrol on a clinical trial – and the American Society of Clinical Oncology (ASCO) is concerned that outdated and restrictive eligibility criteria could be hindering research.


The organisation has used its annual meeting in Chicago to call for some of these outmoded eligibility criteria to be dropped after a study showed that relaxing three rules used to screen patients almost doubled the number of patients on a dummy lung cancer trial.


Oncology Business Review - ASCO Late-Breakers for Monday June 3, 2019

Late-breaking studies featured today at this morning’s press briefing as the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting continues included the phase 3 OSLO-COMET trial, the phase 2 EV-201 trial, and a study suggesting clinical trial participation of patients with lung cancer could be increased by revising eligibility criteria.


Laparoscopic and open resection equally effective for colorectal liver metastases (LBA3516)


Physician's Weekly - ASCO 2019: FDA Launches Project Facilitate to Ease Access to Novel Agents

The FDA says it is making it easier for doctors to access unapproved therapies for cancer patients, but Richard Padzur, MD, is emphatic: the pilot program, called Project Facilitate, only covers drugs in the oncology space.


OncLive - FDA Streamlines Expanded Access for Oncology Agents

The FDA has unveiled what it describes as a pilot “concierge service” for oncologists and patients seeking information and assistance with expanded access (EA) to investigational therapies. The two-pronged program is called Project Facilitate, run by the FDA Oncology Center of Excellence, and EA Navigator, which is operated by the Reagan-Udall Foundation for the FDA.


Genetic Engineering & Biotech News - Will Testing for Tumor Mutational Burden Bring the Same Challenges as Testing for PD-L1?

While PD-L1 testing has become commonplace with immuno-oncology treatment, the multitude of available antibodies, cut-offs, and scoring algorithms makes this biomarker anything but uniform and consistent. Developments over this past year in the diagnostic market hint that tumor mutational burden (TMB) may face the same variability challenges as PD-L1: the results from one TMB test may not be interchangeable with the next.


GenomeWeb - Christiana Care Preparing IND for CRISPR-Based Lung Cancer Therapy

Christiana Care Health System's Gene Editing Institute is preparing to file an investigational new drug application (IND) with the US Food and Drug Administration for a clinical trial protocol that will use CRISPR genome editing to improve the efficacy of chemotherapy for KRAS-positive non-small-cell lung cancer (NSCLC) patients.


The ASCO Post - ASCO Announces New Task Force to Address Rural Cancer Care Gap

ASCO recently announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new Rural Cancer Care Task Force will identify opportunities to close the rural cancer care gap and implement strategies to improve rural cancer care in the United States.